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INTRODUCTION
It has become increasingly clear that the onset of cognitive decline is earlier than previously realized. Recently, it was found that cognitive decline is already evident at the age of 45 years. 1 This has led to the belief that poor cognitive function in old age is the result of a long-term pathological process that spans at least two to three decades. These findings have important consequences because interventions designed to prevent or postpone cognitive decline may be most effective when started at young age. However, effective interventions can only be designed when more insight is gained in mechanisms that underlie early cognitive decline. Because midlife cardiovascular risk factors, such as hypercholesterolemia and hypertension, are associated with cognitive decline in older age, 2 it is likely that cardiovascular risk factors are also associated with cognitive decline at younger age.
Despite the need for a better understanding of the determinants of early cognitive decline, data on the relationship of cardiovascular disease with cognitive function at young age are still limited. Some data point toward a negative effect of modifiable risk factors, such as obesity and smoking, on cognitive performance in young adults. 3, 4 However, it is unclear at what age the negative effects of cardiovascular risk factors on the brain begin.
Elias et al. showed that young adults may be as vulnerable as older adults to the negative effect of hypertension on cognitive function. 5 Thus, there is some evidence that an adverse impact of cardiovascular risk factors on cognitive performance is not limited to older adults.
Cardiovascular risk is often underestimated in young persons because at a young age, individual risk factors may not exceed threshold values. However, risk factors for cardiovascular disease, such as hypertension, dyslipidemia, and diabetes mellitus, often cluster within subjects, and it is generally assumed that they act via shared biological pathways. 6 This has led to the development of multicomponent cardiovascular risk scores that can be used to predict an individual's risk of a cardiovascular event within the next years. [7] [8] [9] By accounting for the conjoint effects of risk factors, they can indicate an increase in cardiovascular risk even if separate risk factors are still subclinical. 8 Thus, cardiovascular risk scores reliably reflect the overall cardiovascular risk profile in young as well as older persons.
Therefore, the aim of this study was to evaluate the association of overall cardiovascular risk profile with cognitive function and to explore this association in various age groups. The study included a large community-based cohort of 3,778 persons aged 35-82 years. 
METHODS

Study Design
The Prevention of REnal and Vascular ENd-stage Disease (PREVEND) study is a prospective cohort study investigating the natural course of microalbuminuria and its association with renal and cardiovascular disease. Details have been described elsewhere. 10 In brief, at baseline 8,592 participants aged 28-75 years were selected from inhabitants of the city of Groningen (Netherlands) based on their urinary albumin excretion. These participants completed the baseline survey in 1997-1998 and were followed over time. 
Cognitive Function
The Ruff Figural Fluency Test (RFFT) was the primary outcome measure for cognitive function. The RFFT was introduced at the third survey of the PREVEND study and requires the participants to draw as many designs as possible within a set time limit, whereas avoiding repetitions. 11 The RFFT is generally seen as a measure of executive function but provides information about various cognitive abilities, such as initiation, planning, divergent reasoning and the ability to switch between different tasks. The RFFT is sensitive to changes in cognitive performance in young and old persons. 11, 12 The main outcome measure is the total number of unique designs which ranges from 0 to 175 points (worst and best score, respectively).
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The Visual Association Test (VAT) was used as a secondary outcome measure for cognitive function. The VAT is a brief learning task that is designed to detect anterograde amnesia. The test consists of six drawings of pairs of interacting objects of animals. The person is asked to name each object and, later, is presented with one object from the pair and asked to name the other. The lowest (worst) score is 0 points, and the highest (best) score is 12 points. 
Measurements of Risk Score Components
As the FRS was validated in subjects without a cardiovascular history, 8 Subjects were categorized as APOE ε4 carriers (allele ε2/ε4 or ε3/ε4 or ε4/ε4) or noncarriers (ε2/ε2 or ε2/ε3 or ε3/ε3).
Statistical Analysis
Normally distributed data are presented as means and standard deviation (SD), and skewed data are presented as medians and interquartile range. The association of RFFT score with FRS was analyzed by four multiple linear regression models. In all models, RFFT score (points) was the dependent variable. In the first model, the association of RFFT score with FRS was investigated for the total study population and each separate age group (35-44, 45-54, 55-64, 65-74 and ≥75 years). The independent variables of this model were FRS (points) and educational level (categories). In the second model, it was investigated whether the association of RFFT score with FRS was dependent on age group. In this model, the independent variables were FRS (points), age group (categories), the product term FRS x age group, and educational level (categories). In the third model, the association of RFFT score with each separate component of the FRS was analyzed. The independent variables of this model were age (years), female gender (yes/no), diabetes mellitus (yes/no), current smoker (yes/no), systolic blood pressure (mmHg), use of blood pressure-lowering agents (yes/no), total cholesterol (mmol/L), HDL cholesterol (mmol/L), and educational level (categories). To investigate whether there was a dose-response effect of smoking, we also ran this model with smoking categorized into non-smoking, light smoking (1-15 cigarettes/day) and heavy smoking (≥16 cigarettes/day).
Finally, in the fourth model, it was evaluated whether the association of RFFT score with FRS was dependent on APOE ε4 carriership. In this model, the independent variables were FRS (points), APOE ε4 carriership (yes/no), the product term FRS x APOE ε4 carriership, and educational level (categories).
Similar analyses were performed for VAT score as cognitive outcome measure.
Because of its skewed distribution, VAT score was dichotomized at the median into low performance (≤10 points) and high performance (≥11 points). Accordingly, the association of VAT performance with FRS was evaluated by logistic regression analysis (adjusted for educational level).
Sensitivity Analyses
Various a priori-defined sensitivity analyses were performed. First, the analyses were repeated in the total study population, including persons with a cardiovascular disease history. Second, the PREVEND cohort is enriched for subjects with higher levels of albuminuria which may be negatively associated with cognitive function. 15, 16 Therefore, the analyses were repeated in a subsample of the cohort which is representative for the general population (prevalence of elevated albuminuria 7.5%). 10 Third, the analyses were limited to persons aged 35-74 years, because the FRS was only validated for persons <75 years. 8 Finally, to investigate the generalizability of our findings, analyses were repeated with other cardiovascular risk scores, like the Framingham risk score for coronary heart disease and the SCORE risk system which was developed in a European population.
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RESULTS
Study population
Overall, a total of 5,862 subjects completed the third survey, of which 1,271 participants (22%) refused to perform the RFFT and 433 (7%) had incomplete RFFT data. 15 Of those with a complete RFFT score, subjects with a history of cardiovascular disease or stroke (n = 311; 5%) or with missing data on components of the FRS or educational level (n = 66; 1%) were excluded. Three participants aged <35 years were excluded because their number was too small to form a separate age group. Thus, the final study population included 3,778 persons (51% men) with an age range from 35 to 82 years with mean (SD) age 54 (11) years (Table 1) . Mean RFFT score (SD) was 70 (26) points. RFFT score decreased with increasing age and increased with each higher level of education (P trend <0.001). 12 FRS ranged from -3 to +32 points with a mean (SD) of 10 (6) points and increased with increasing age (Table 2) .
RFFT and Framingham Risk Score
The RFFT score was dependent on the FRS ( 
RFFT and Framingham Risk Score per Age Group
The negative association of FRS with RFFT score was not only found in the overall study population but also in all age groups, including the youngest (35-44 years). Low performance (≤10 points), n (%) High performance (≥11 points), n (%) Unknown, n (%) All 3778 (100) 54 (11) 1927 (51) 900 (24) 1221 (32) 904 (24) 564 (15) 189 (5) 1173 (31) 204 (5) 893 (24) 27 (4) 125 (17) (15) 5 (4) 11 (4) 13 (4) 17 (4) 19 (4) 73 (23) 64 (21) 57 (20) 49 (17) 43 (16) 5 (4) 9 (4) 13 (4) 16 (4) 19 (3) 82 (25) 74 (23) 66 (20) 54 (16) 46 (17) 4 (4) 9 (4) 12 (4) 16 (4) 19 (3) 93 (21) 87 (21) 75 (22) 61 (20) 55 (25) 3 (3) 7 (4) 12 (4) 16 (4) 19 (3) 85 (24) 
RFFT and Separate Risk Factors
In univariate analyses, RFFT score was not only associated with the overall FRS, but also with each separate risk factor component of the FRS, except for gender (data not shown).
However, in multiple linear regression analysis (with adjustment for educational level) only age, DM, HDL-cholesterol and smoking were statistically significantly associated with RFFT score (Table 3) . Compared with non-smoking, smoking 1 to 15 cigarettes/day was associated with a decrease of 2.41 points in RFFT score (95%CI, -4.40 to -0.53; P = 0.02), and smoking ≥16 cigarettes/day was associated with a decrease of 3.43 points in RFFT score (95%CI, -5.90 to -0.96; P = 0.007). 
Effect of APOE ε4 carriership
The study population included 1,060 APOE ε4 carriers and 2,472 noncarriers ( Table 1 ).
The association of RFFT score with FRS was not dependent on APOE ε4 carriership (B-coefficient, 2.49; 95%CI, -0.77 to 5.74; P = 0.13), and there was no statistically significant interaction between APOE ε4 carriership and FRS (P = 0.84). Similar results were found if all APOE ε2 carriers were excluded.
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VAT and Framingham Risk Score
Analysis of the association of VAT score with FRS yielded similar findings. VAT scores were obtained in 3,706 subjects (98%). Overall, 58% (n = 2,176) had a VAT score of ≤10 (Table 1 ). The percentage with low performance gradually increased from 33% in the group with the lowest FRS to 78% in the group with the highest FRS (P <0.001) (Figure 3) . A similar increase was found in all age groups except one (Figure 4 ). The odds ratio for low performance on the VAT increased by factor 1.08 (95%CI, 1.07-1.10; P <0.001) per point increase in FRS (adjusted for educational level). 
FRS indicates Framingham Risk
Score for general cardiovascular disease and includes age, gender, diabetes mellitus, current smoker status, systolic blood pressure, use of blood pressure-lowering agents, total cholesterol, and HDLcholesterol.
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Sensitivity Analyses
Various sensitivity analyses gave essentially similar results. First, if persons with a history of cardiovascular events and stroke were not excluded from the analysis, RFFT score decreased by 1.54 points (95%CI, -1.66 to -1.43; P <0.001) per point increase in FRS. If the analysis was limited to the subsample that was comparable to the general population with regard to microalbuminuria, the RFFT decreased by 1.45 points (95%CI, -1.65 to -1.24; P <0.001) per point increase in FRS. Also, results did not change in case the analysis was limited to persons aged <75 years (n = 3,589) (B-coefficient, -1.44; 95%CI, -1.57 to -1.30; P <.001). Finally, if the analyses were repeated with the FRS for coronary heart disease or the SCORE risk system as independent variable, RFFT score decreased by 1.51 point (95%CI, -1.66 to -1.36; P <0.001), or 1.86 point (95%CI, -2.13 to -1.59; P <0.001) per point increase in risk score, respectively. In all sensitivity analyses, the negative association of RFFT score with FRS (or alternative risk scores) persisted in all age groups (data not shown).
DISCUSSION
In this large population-based study, a worse general cardiovascular risk profile was associated with poorer cognitive function. Importantly, this negative association was not only found in older persons, but also already present in young and middle-aged subgroups.
Cardiovascular risk profile was based on eight individual risk factors. Within this composite risk score, the factors age, diabetes mellitus, smoking, and HDL-cholesterol proved to be the strongest determinants of cognitive function.
Biological Changes in Early Adulthood
It is generally assumed that the presence of cardiovascular risk factors at young age has important consequences later in life. Numerous studies showed that early presence of cardiovascular risk factors leads to the acceleration of atherosclerosis in young people and increases the long-term risks of cardiovascular disease. 17, 18 Autopsy studies showed that hyperlipidemia, hypertension, smoking and hyperglycemia are associated with the prevalence and severity of atherosclerotic lesions in young people. 19 We showed that increased cardiovascular risk profile also associates with cognitive function at a young age. To our knowledge only two previous studies reported on the relationship between overall cardiovascular risk profile and cognitive function with disparate findings. 20 21 Besides, the results cannot be extended towards subjects <50 years of age, because both studies populations did not include younger adults. 20, 21 Our study shows a clear association between overall cardiovascular risk and cognitive function. Most importantly, this association was independent of age and was found also in young adults.
Interestingly, the association of cognitive function with cardiovascular risk in young adults matches the association of subclinical biological changes with cardiovascular risk in this age group. The most important biological changes indicating early cardiovascular disease include increased intimal-media thickness, carotid coronary artery calcification, pulse pressure, and arterial pulse wave velocity. 22 Several studies showed that an adverse cardiovascular risk factor profile predicts increased intimal-media thickness, pulse wave velocity, and coronary artery calcification in young adults. 23, 24 It seems plausible that the presence of these subclinical biological changes is associated with adverse outcome with respect to cognitive function later in life. Indeed, three previous large population-based studies showed that premature atherosclerotic changes predict clinically relevant cognitive decline, [25] [26] [27] although in one other study the results were equivocal.
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Implications
Many risk factors for premature atherosclerosis are modifiable. This strengthens the idea that early intervention at a young age may contribute to better cognitive function later in life. In this study, we found two risk factors, smoking and diabetes mellitus that were strong determinants of cognitive function and can be changed or controlled by effective interventions.
Our data suggested a dose-response relationship between smoking and cognitive function because heavy smokers had lower performance on the cognitive test than light smokers and non-smokers. However, nicotine dependence is still highly prevalent in young adults and there has been no decline in smoking among young adults since 2003. 29 Nevertheless, it is likely that smoking cessation has a beneficial effect on cognitive function. 30 Therefore, our study underlines the need for effective smoking cessation treatmentsnot only for the prevention of cancer, cardiovascular events and stroke but also for the prevention of cognitive decline.
Diabetes mellitus was also negatively associated with cognitive function in our study.
It is generally assumed that the effect of diabetes mellitus is at least partially modifiable because improved glucose regulation ameliorates important negative outcomes. 31 
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Until now, however, it was not clear whether improved glucose regulation also ameliorates cognitive decline. In two intervention studies, intensive glucose-lowering treatment was not associated with better cognitive outcomes in middle-aged and elderly persons with type 2 diabetes mellitus. 32, 33 However, both studies were of relatively short duration and, possibly, a longer time frame is necessary to show that stricter glucose regulation is beneficial for cognitive function.
Strengths and Limitations
Some limitations of this study must be acknowledged. First, the primary outcome measure was based on a single cognitive test. However, the RFFT is a composite measure of very different cognitive abilities, such as initiation, planning, divergent reasoning and the ability to switch between different tasks. In addition, because of its wide score range, the RFFT is not limited by a ceiling or floor effect and, thereby, sensitive to subtle changes in cognitive performance in young and old persons. 12 Also, the main findings were confirmed in the analyses with the VAT as cognitive outcome measure. Second, the PREVEND cohort is enriched for elevated albuminuria, which could induce selection bias, because albuminuria is a risk factor for cardiovascular disease. 15 However, a sensitivity analysis in a subsample, representative for the general population, did not change results. Finally, the cross-sectional design of this study does not formally allow a firm conclusion on a causal relationship. For example, it is possible that persons with low cardiovascular risk and poor cognitive performance were underrepresented in our study. However, there were no clear signs of selection bias. Moreover, the association of cardiovascular risk profile with cognitive function that we found in this study seems plausible on biological grounds and is supported by findings of other studies. Nevertheless, the causality of this relationship should be confirmed in longitudinal studies.
Despite these limitations, our study also has several strengths. We included a large community-based population with a wide age range, whereas others used selected populations, such as the elderly or subjects with diabetes mellitus. The generalizability of our data is, therefore, well preserved. In contrast to many previous studies, we explored the 
Conclusions
In this large population-based cohort, a worse cardiovascular risk profile was associated with poorer cognitive function. This association was already present in young adults. In our opinion, there is need for further investigation of cognitive function as a new clinical endpoint in the light of cardiovascular burden.
